MedTrace Logo

Biomarkers in HF: Circulating Biomarkers of Fibrosis and Cardiovascular Disease

NCT05826821 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 107

Last updated 2023-04-24

No results posted yet for this study

Summary

Heart failure with preserved ejection fraction (HFpEF) represents one of the largest unmet needs in cardiovascular medicine. Heart muscle scarring (myocardial fibrosis) is a key HFpEF disease mechanism and represents an important therapeutic target.

Myocardial fibrosis can be measured non-invasively using the cardiovascular magnetic resonance imaging (MRI) extracellular volume (ECV) technique. However, some patients cannot undergo MRI scanning, and it is expensive. Circulating biomarkers in the blood that are sensitive to changes in myocardial fibrosis would represent an attractive cheaper and accessible alternative.

This study aims to assess baseline levels of, and longitudinal change in, circulating biomarkers relating to fibrosis and cardiovascular disease in gifted samples from PIROUETTE trial participants, and evaluate the relationship between the biomarkers, anti-fibrotic treatment response and other study measurements.

Conditions

Interventions

DRUG

Pirfenidone

Intervention drug

Sponsors & Collaborators

  • Manchester University NHS Foundation Trust

    lead OTHER_GOV

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-02
Primary Completion
2019-11-29
Completion
2020-04-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05826821 on ClinicalTrials.gov